flow trial semaglutide kidney outcomes 2024 kidney outcomes
flow trial semaglutide kidney outcomes 2024 kidney outcomes - Semaglutide FLOW trial semaglutide reduced the risk of major kidney outcomes FLOW Trial Semaglutide Kidney Outcomes 2024: A Paradigm Shift in Diabetic Kidney Disease Management
FLOW TrialNEJM The groundbreaking FLOW trial has unveiled significant positive kidney outcomes for patients with type 2 diabetes and chronic kidney disease (CKD) when treated with semaglutideGlucagon-like Peptide-1 Receptor Agonists: New Evidence .... These pivotal 2024 findings, emanating from a robust clinical study, introduce a new era in the treatment and management of diabetic kidney complicationsEffects of Semaglutide on Chronic Kidney Disease in Patients .... The semaglutide kidney outcomes data from the FLOW trial indicate a substantial reduction in the risk of clinically important kidney complications and cardiovascular events, marking a significant advancement in patient care.
The FLOW trial, a large-scale, once-weekly semaglutide 1.0 mg study, was designed to comprehensively evaluate the efficacy and safety of this GLP-1 receptor agonist in individuals diagnosed with both type 2 diabetes and chronic kidney disease. The FLOW trial's primary results demonstrate that semaglutide significantly improved renal and cardiovascular health. Specifically, semaglutide reduced the risk of major kidney outcomes by an impressive 24%, a finding that has been consistently reported across multiple analyses and publications stemming from the trial.作者：KR Tuttle·2024—Conclusion:Semaglutide safely reduced risks of major kidney outcomesirrespective of CKD severity defined by baseline eGFR or UACR in participants with T2D ... This translates to a tangible benefit for patients, suggesting semaglutide can slow down the growth and worsening of chronic kidney disease.
The FLOW trial evaluated a composite primary outcome that included kidney failure, sustained a 50% or greater reduction in estimated glomerular filtration rate (eGFR) from baseline, or death from kidney-related or cardiovascular causes. The results of the FLOW trial indicated that semaglutide was superior to placebo in achieving this composite endpointEffects of Semaglutide on Chronic Kidney Disease in Patients .... The Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes are now clearer than ever, with the FLOW trial providing definitive evidence. This means that semaglutide significantly decreases the risk of progression of kidney disease in this vulnerable population11. TheFLOW(Evaluate Renal Function with.SemaglutideOnce Weekly)trialassessed the ef- ficacy and safety of subcutaneoussemaglutideat a dose of 1.0 mg once weekly for the prevention ofkidneyfailure, substantial loss ofkidneyfunc- tion, and death fromkidney-related or cardiovas- cular causes ....
Furthermore, the FLOW trial analysis has also highlighted that semaglutide safely reduced risks of major kidney outcomes irrespective of the baseline severity of CKD, as defined by eGFR or albumin-to-creatinine ratio (UACR). This broad applicability suggests that a wide range of patients with diabetic kidney disease could potentially benefit from this therapy. The Semaglutide FLOW trial results are not only statistically significant but also clinically meaningful, offering hope for improved long-term health and reduced morbidity作者：KW Mahaffey·2025·被引用次数：41—In the FLOW trial,semaglutide reduced the risks of kidney and cardiovascular (CV) outcomesand death in participants with type 2 diabetes ....
Beyond its direct impact on kidney health, the semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality. Analyses from the FLOW trial have consistently shown that semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants. This dual benefit underscores the pleiotropic effects of semaglutide, extending its protective influence to the cardiovascular system, a crucial aspect given the high comorbidity rates in patients with diabetes and CKD. In fact, studies have reported that semaglutide was found to have a substantial CV benefit in these patients.
The impact of these findings is already being felt in clinical practice guidelines. For instance, the American Diabetes Association's 2025 guideline has incorporated results from the FLOW trial into their recommendations2025年6月23日—Semaglutidereduced the risk of death, including cardiovascular death, among patients in theFLOW trial, who had chronickidneydisease .... The FLOW trial results are also consistent with findings from meta-analyses assessing secondary kidney endpoints in previous trials, further solidifying the evidence base for semaglutide in kidney protection.
The specific dosage and administration regimen used in the FLOW trial involved once-weekly semaglutide 1作者：KW Mahaffey·2025·被引用次数：41—In the FLOW trial,semaglutide reduced the risks of kidney and cardiovascular (CV) outcomesand death in participants with type 2 diabetes and chronic kidney ....0 mg. This regimen proved effective in not only slowing kidney disease progression but also in reducing the risk of kidney and cardiovascular deaths by 24%. This implies that semaglutide 1.In primary FLOW study results,semaglutide reduced the risk of major kidney outcomes, cardiovascular events, and death from any cause by 24% (N Engl J Med. ...0 mg once weekly reduced the risk of major kidney disease events and associated complications.作者：V Perkovic·2024·被引用次数：1393—Semaglutidereduced the risk of clinically importantkidney outcomesand death from cardiovascular causes in patients with type 2 diabetes ... The consistent findings across various analyses of the FLOW trial, including sub-analyses on mortality, reinforce the comprehensive benefits of this treatment.
In conclusion, the FLOW trial semaglutide kidney outcomes 2024 represent a significant milestone in nephrology and endocrinologyGet With the FLOW! in. The data unequivocally demonstrate that semaglutide drastically reduces the risk of major kidney disease events, MACE, and all-cause death, while simultaneously slowing the loss of kidney function. This pioneering study has provided robust evidence that semaglutide is a transformative therapy for individuals battling diabetic kidney disease, offering improved renal and cardiovascular health for millions worldwide.Kidney Week The FLOW trial has truly changed the landscape of diabetic kidney disease management.